Compana built a pet-care portfolio that stretches from the living room to the barnyard. Its wager is that expertise across species - and a talent for integrating niche brands - can turn an old feed business into a modern wellness platform.
Sporos Bioventures is a Houston-based private biotechnology company that builds and operates a portfolio of oncology and immune-disease startups under one roof. Rather than launching companies one at a time, Sporos pools capital, drug-discovery infrastructure, and operational expertise across multiple programs - including Tvardi Therapeutics, Asylia Therapeutics, Nirogy Therapeutics, Stellanova Therapeutics, and its internal Sporos BioDiscovery group - to move targeted cancer therapies from idea to early clinical trials faster and with less duplicated risk.